Zydus Infringed AstraZeneca's Diabetes Drug IP, Judge Rules

By Craig Clough · October 15, 2021, 9:17 PM EDT

A Delaware federal judge held Friday that Zydus Pharmaceuticals infringed an AstraZeneca patent for a diabetes drug, saying Zydus failed during a four-day bench trial to prove that any of the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

AstraZeneca AB v. Zydus Pharmaceuticals (USA) Inc.

Case Number

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

May 01, 2018

Recent Articles By Craig

May 27, 2025
Eli Lilly Inks $1B Deal For Non-Opioid Pain-Drug Maker
May 23, 2025
Meta, App Maker Flo Can't Escape All Of Privacy Class Action
May 19, 2025
Feds Get Early Win In Drugmakers' Suit Over 340B Rebates
May 13, 2025
Asterisk Doesn't Save CVS In Sanitizer Row, 9th Circ. Told
May 05, 2025
20 AGs Sue To Stop 'Illegal Dismantling' Of HHS
April 29, 2025
Gilead Will Pay $202M In DOJ Deal Over Drug Kickbacks
February 13, 2025
UnitedHealth Can't Escape All Claims In AI Denial Suit
January 13, 2025
California's AG Warns Businesses State Is Not AI 'Wild West'
December 17, 2024
UNC Doctor Can't Shield Minor Transgender Patients' Records
December 17, 2024
Stanford Profs Say Roche's Trade Secret Claims Time-Barred